论文部分内容阅读
洛赛克(Losec)作为一种新型的胃酸抑制剂近年来已被逐渐广泛应用于临床,许多报道证实其疗效优于H_2受体拮抗剂。我们于1991年8月至1992年3月对50例活动性消化性溃疡患者分别用Losec和雷尼替丁(RAN)治疗,观察了两组药物的近期疗效和抑酸作用,报告如下。(一)对象和方法1.病例选择:经胃镜检查诊断为活动性消化性溃疡病人50例随机分成两组:Losec组:26例,其中男性25例,女性1例,年龄19～63岁。十二指肠球部溃疡(DU)23例、胃溃疡(GU)1例、复合性溃疡2例,其中3例为雷尼替丁治疗半年以上无效的顽固性溃疡;RAN组:24例,其中男性20例,女性4例,年龄14～60岁。DU23例,GU1例。两组溃
Losec, a new type of gastric acid inhibitor, has been widely used clinically in recent years. Many reports confirm that Losec is better than H 2 receptor antagonist. We in August 1991 to March 1992 for 50 patients with active peptic ulcer patients were treated with Losec and ranitidine (RAN), the two groups of drugs to observe the short-term efficacy and inhibition of acid, the report is as follows. (I) Subjects and Methods 1. Case Selection: Fifty patients diagnosed with active peptic ulcer by gastroscopy were randomly divided into two groups: Losec group: 26 cases, including 25 males and 1 female, aged 19-63 years. 23 cases of duodenal ulcer (DU), 1 case of gastric ulcer (GU) and 2 cases of complex ulcer. Among them, 3 cases were refractory ulcer with ranitidine treatment for more than six months; RAN group: 24 cases, Including 20 males and 4 females, aged 14 to 60 years. DU23 cases, GU1 cases. Two groups collapse